pp-218 Solution for injection

Indication: Obesity (overweight/obese adults; severe obesity) Clinical stage: Phase 2 — FDA-cleared and initiated H2 2025 (NCT07205900) Modality: Biological (long-acting GLP-1/GIP/GCG triple receptor agonist peptide — NBE) Mechanism / Target: Balanced co-agonist of GLP-1 receptor (appetite suppression and satiety), GIP receptor (metabolic and adipose function improvement), and glucagon receptor (energy expenditure, lipolysis); optimised activity balance enhances weight loss quantity and quality while reducing lean muscle loss; Hanmi LAPSCOVERY technology confers extended half-life for once-weekly SC dosing Route / form: Subcutaneous injection (once weekly) Differentiation: GLP-1/GIP/GCG triple agonist with potential >25% body weight loss (bariatric surgery-level efficacy); Phase 1 data showed ≈5% weight loss in 4 weeks with favourable safety; Phase 2 initiated H2 2025; best-in-class metabolic profile vs. dual agonists;